SGLT2 inhibitor counteracts NLRP3 inflammasome via tubular metabolite itaconate in fibrosis kidney

Acute Kidney Injury Events in Patients With Type 2 Diabetes Using SGLT2 Inhibitors Versus Other Glucose-Lowering Drugs: A Retrospective Cohort Study

(2020) Christie Rampersad et al.   AMERICAN JOURNAL OF KIDNEY DISEASES

Use of sodium–glucose cotransporter-2 inhibitors and risk of acute kidney injury in older adults with diabetes: a population-based cohort study

(2020) Carina Iskander et al.   CANADIAN MEDICAL ASSOCIATION JOURNAL

The role of renal hypoxia in the pathogenesis of diabetic kidney disease: a promising target for newer renoprotective agents including SGLT2 inhibitors?

(2020) Anne C. Hesp et al.   KIDNEY INTERNATIONAL

Targeting the progression of chronic kidney disease

(2020) Marta Ruiz-Ortega et al.   Nature Reviews Nephrology

Use of sodium-glucose co-transporter 2 inhibitors and risk of serious renal events: Scandinavian cohort study

(2020) Björn Pasternak et al.   BMJ-British Medical Journal

SGLT2 Inhibition Mediates Protection from Diabetic Kidney Disease by Promoting Ketone Body-Induced mTORC1 Inhibition

(2020) Issei Tomita et al.   Cell Metabolism

The Immunomodulatory Metabolite Itaconate Modifies NLRP3 and Inhibits Inflammasome Activation

(2020) Alexander Hooftman et al.   Cell Metabolism

Chemoproteomic Profiling of Itaconation by Bioorthogonal Probes in Inflammatory Macrophages

(2020) Wei Qin et al.   JOURNAL OF THE AMERICAN CHEMICAL SOCIETY

The dapagliflozin and prevention of adverse outcomes in chronic kidney disease (DAPA-CKD) trial: baseline characteristics

(2020) David C Wheeler et al.   NEPHROLOGY DIALYSIS TRANSPLANTATION

Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure

(2020) Milton Packer et al.   NEW ENGLAND JOURNAL OF MEDICINE

Dapagliflozin in Patients with Chronic Kidney Disease

(2020) Hiddo J.L. Heerspink et al.   NEW ENGLAND JOURNAL OF MEDICINE

SGLT2 Inhibition Does Not Affect Myocardial Fatty Acid Oxidation or Uptake, But Reduces Myocardial Glucose Uptake and Blood Flow in Individuals With Type 2 Diabetes– a Randomized Double-Blind, Placebo-Controlled Crossover Trial

(2020) Katrine M. Lauritsen et al.   DIABETES

The PKM2 activator TEPP‐46 suppresses kidney fibrosis via inhibition of the EMT program and aberrant glycolysis associated with suppression of HIF‐1α accumulation

(2020) Haijie Liu et al.   Journal of Diabetes Investigation

Comparative safety of the sodium glucose co-transporter 2 (SGLT2) inhibitors: a systematic review and meta-analysis

(2019) Jennifer R Donnan et al.   BMJ Open

Canagliflozin reduces inflammation and fibrosis biomarkers: a potential mechanism of action for beneficial effects of SGLT2 inhibitors in diabetic kidney disease

(2019) Hiddo J. L. Heerspink et al.   DIABETOLOGIA

Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy

(2019) Vlado Perkovic et al.   NEW ENGLAND JOURNAL OF MEDICINE

S-glycosylation-based cysteine profiling reveals regulation of glycolysis by itaconate

(2019) Wei Qin et al.   Nature Chemical Biology

SGLT2 inhibitors for the prevention of kidney failure in patients with type 2 diabetes: a systematic review and meta-analysis

(2019) Brendon L Neuen et al.   Lancet Diabetes & Endocrinology

4-Octyl itaconate inhibits aerobic glycolysis by targeting GAPDH to exert anti-inflammatory effects

(2019) Shan-Ting Liao et al.   Nature Communications

Rationale and protocol of the Dapagliflozin And Prevention of Adverse outcomes in Chronic Kidney Disease (DAPA-CKD) randomized controlled trial

(2019) Hiddo J L Heerspink et al.   NEPHROLOGY DIALYSIS TRANSPLANTATION

Acute kidney injury and adverse renal events in patients receiving SGLT2-inhibitors: A systematic review and meta-analysis

(2019) Jan Menne et al.   PLOS MEDICINE

Kidney outcomes associated with use of SGLT2 inhibitors in real-world clinical practice (CVD-REAL 3): a multinational observational cohort study

(2019) Hiddo J L Heerspink et al.   Lancet Diabetes & Endocrinology

New Diabetes Therapies and Diabetic Kidney Disease Progression: the Role of SGLT-2 Inhibitors

(2018) Claire C. J. Dekkers et al.   Current Diabetes Reports

Sodium–glucose cotransporter 2 inhibition normalizes glucose metabolism and suppresses oxidative stress in the kidneys of diabetic mice

(2018) Shinji Tanaka et al.   KIDNEY INTERNATIONAL

Pooled analysis of Phase III trials indicate contrasting influences of renal function on blood pressure, body weight, and HbA1c reductions with empagliflozin

(2018) David Z.I. Cherney et al.   KIDNEY INTERNATIONAL

Effects of the sodium–glucose co-transporter 2 inhibitor dapagliflozin in patients with type 2 diabetes and Stages 3b–4 chronic kidney disease

(2018) Claire C J Dekkers et al.   NEPHROLOGY DIALYSIS TRANSPLANTATION

TWEAK and RIPK1 mediate a second wave of cell death during AKI

(2018) Diego Martin-Sanchez et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Acute renal outcomes with SGLT-2 inhibitors - real world data analysis

(2018) Avivit Cahn et al.   DIABETES OBESITY & METABOLISM

A sodium-glucose cotransporter 2 inhibitor attenuates renal capillary injury and fibrosis by a vascular endothelial growth factor–dependent pathway after renal injury in mice

(2018) Yifan Zhang et al.   KIDNEY INTERNATIONAL

Itaconate is an anti-inflammatory metabolite that activates Nrf2 via alkylation of KEAP1

(2018) Evanna L. Mills et al.   NATURE

UCP2-dependent improvement of mitochondrial dynamics protects against acute kidney injury

(2018) Nan Qin et al.   JOURNAL OF PATHOLOGY

Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes

(2018) Stephen D. Wiviott et al.   NEW ENGLAND JOURNAL OF MEDICINE

Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes

(2017) Bruce Neal et al.   NEW ENGLAND JOURNAL OF MEDICINE

Itaconate Links Inhibition of Succinate Dehydrogenase with Macrophage Metabolic Remodeling and Regulation of Inflammation

(2016) Vicky Lampropoulou et al.   Cell Metabolism

Sodium Glucose Cotransporter 2 Inhibitors in the Treatment of Diabetes Mellitus

(2016) Hiddo J.L. Heerspink et al.   CIRCULATION

K + Efflux-Independent NLRP3 Inflammasome Activation by Small Molecules Targeting Mitochondria

(2016) Christina J. Groß et al.   IMMUNITY

Ferroptosis, but Not Necroptosis, Is Important in Nephrotoxic Folic Acid–Induced AKI

(2016) Diego Martin-Sanchez et al.   JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY

Pyruvate Kinase M2 Regulates Hif-1α Activity and IL-1β Induction and Is a Critical Determinant of the Warburg Effect in LPS-Activated Macrophages

(2015) Eva M. Palsson-McDermott et al.   Cell Metabolism

Network Integration of Parallel Metabolic and Transcriptional Data Reveals Metabolic Modules that Regulate Macrophage Polarization

(2015) Abhishek K. Jha et al.   IMMUNITY

UCP2-induced fatty acid synthase promotes NLRP3 inflammasome activation during sepsis

(2015) Jong-Seok Moon et al.   JOURNAL OF CLINICAL INVESTIGATION

The ketone metabolite β-hydroxybutyrate blocks NLRP3 inflammasome–mediated inflammatory disease

(2015) Yun-Hee Youm et al.   NATURE MEDICINE

Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes

(2015) Bernard Zinman et al.   NEW ENGLAND JOURNAL OF MEDICINE

Mechanisms and Functions of Inflammasomes

(2014) Mohamed Lamkanfi et al.   CELL

Defective fatty acid oxidation in renal tubular epithelial cells has a key role in kidney fibrosis development

(2014) Hyun Mi Kang et al.   NATURE MEDICINE

Empagliflozin improves glycaemic and weight control as add-on therapy to pioglitazone or pioglitazone plus metformin in patients with type 2 diabetes: a 24-week, randomized, placebo-controlled trial

(2013) C. S. Kovacs et al.   DIABETES OBESITY & METABOLISM

Rheb/mTORC1 Signaling Promotes Kidney Fibroblast Activation and Fibrosis

(2013) L. Jiang et al.   JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY

The mitochondrial citrate carrier: a new player in inflammation

(2011) Vittoria Infantino et al.   BIOCHEMICAL JOURNAL

Epithelial cell cycle arrest in G2/M mediates kidney fibrosis after injury

(2010) Li Yang et al.   NATURE MEDICINE